Mounjaro reduces abdominal fat indirectly by suppressing appetite and slowing gastric emptying, leading to sustained caloric deficit and overall fat loss, including visceral and subcutaneous fat around the abdomen, when combined with diet and exercise
despite being taken as a daily pill rather than injection, it contains the same active ingredient and allegedly carries similar risks Mounjaro (tirzepatide): Manufactured by Eli Lilly and approved in May 2022, this medication works as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, offering enhanced blood sugar control and weight loss effects but also allegedly causing severe gastrointestinal injuries similar to semaglutide products Trulicity (dulaglutide): Eli Lillys once-weekly GLP-1 injection approved in 2014 for type 2 diabetes
No drug in American pharmaceutical history had been more aggressively protected through patent thickets and settlement agreements
PMID: 12475787
PSA: As high-demand GLP-1 drugs become harder to get, the FDA is warning consumers that counterfeit Ozempic may be in circulation
In fact, it may even act as a pro-oxidant in some cases
